- Home
- DJCO vs ANAB Comparison
DJCO vs ANAB Comparison
Compare DJCO & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DJCO
- ANAB
- Stock Information
- Founded
- DJCO 1987
- ANAB 2005
- Country
- DJCO United States
- ANAB United States
- Employees
- DJCO N/A
- ANAB N/A
- Industry
- DJCO Newspapers/Magazines
- ANAB Biotechnology: Pharmaceutical Preparations
- Sector
- DJCO Consumer Discretionary
- ANAB Health Care
- Exchange
- DJCO Nasdaq
- ANAB Nasdaq
- Market Cap
- DJCO 793.7M
- ANAB 759.5M
- IPO Year
- DJCO N/A
- ANAB 2017
- Fundamental
- Price
- DJCO $394.50
- ANAB $18.95
- Analyst Decision
- DJCO
- ANAB Buy
- Analyst Count
- DJCO 0
- ANAB 10
- Target Price
- DJCO N/A
- ANAB $36.38
- AVG Volume (30 Days)
- DJCO 17.8K
- ANAB 933.5K
- Earning Date
- DJCO 05-13-2025
- ANAB 05-08-2025
- Dividend Yield
- DJCO N/A
- ANAB N/A
- EPS Growth
- DJCO 370.42
- ANAB N/A
- EPS
- DJCO 55.48
- ANAB N/A
- Revenue
- DJCO $71,642,000.00
- ANAB $91,280,000.00
- Revenue This Year
- DJCO N/A
- ANAB N/A
- Revenue Next Year
- DJCO N/A
- ANAB $59.43
- P/E Ratio
- DJCO $7.39
- ANAB N/A
- Revenue Growth
- DJCO 0.34
- ANAB 432.03
- 52 Week Low
- DJCO $333.29
- ANAB $12.21
- 52 Week High
- DJCO $602.00
- ANAB $41.31
- Technical
- Relative Strength Index (RSI)
- DJCO 45.87
- ANAB 59.57
- Support Level
- DJCO $396.41
- ANAB $17.50
- Resistance Level
- DJCO $412.20
- ANAB $20.72
- Average True Range (ATR)
- DJCO 10.46
- ANAB 1.38
- MACD
- DJCO 3.62
- ANAB 0.23
- Stochastic Oscillator
- DJCO 55.21
- ANAB 67.22
About DJCO Daily Journal Corp. (S.C.)
Daily Journal Corp publishes newspapers and websites covering California and Arizona and produces several specialized information services. The company operates in two segments: Traditional business and Journal Technologies. It also serves as a newspaper representative specializing in public notice advertising. The majority of revenue is generated from the Journal Technologies segment.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).